Maxim Group

In a report published Wednesday, Maxim Group reiterated its Buy rating on Onyx Pharmaceuticals (NASDAQ: ONXX), and raised its price target from $92.00 to $95.00. Maxim Group noted, “We believe Kyprolis sales are the major near-term driver of ONXX. Our randomized talks with oncologists suggest that...

In a report published Wednesday, Maxim Group reiterated its Buy rating on Qihoo 360 Technology (NYSE: QIHU), and raised its price target from $21.00 to $25.00. Maxim Group noted, “Last night QIHU reported 2Q12 results. Revenue was $72.8M, modestly higher than our estimate of $72.2M and consensus...

In a report published Friday, Maxim Group reiterated its Sell rating and $9.00 price target on First Solar (NASDAQ: FSLR). Maxim Group noted, “FSLR's stock has jumped 47% (vs. 2% for the S&P 500) since earnings, likely due to lopsided sentiment and a misinterpretation that its LT outlook is...

In a report published Wednesday, Maxim Group reiterated its Buy rating and $38.00 price target on Cree (NASDAQ: CREE). Maxim Group noted, “In the face of revenue growth/margin concerns, CREE's FY4Q12 results and FY1Q13 guidance, in our view, set the stage for a recovery in FY13 with LED Lighting...

In a report published Wednesday, Maxim Group reiterated its Hold rating on Renren (NYSE: RENN). Maxim Group noted, “Management attributed the ad revenue decline to cutbacks of ad budgets, especially by apparel advertisers, under a slowing economy and intensive competition from similar but better...

Maxim Group raised its rating on Vringo (NYSE: VRNG) from Not Rated to Buy with a newly established $6.50 price target per share. Maxim Group noted, "VRNG is an emerging software company with a limited track record and considerable downside if it loses its patent lawsuit against Google (GOOG, $...

In a report published Friday, Maxim Group reiterated its Buy rating on Ariad Pharmaceuticals (NASDAQ: ARIA), and raised its price target from $20.00 to $24.00. Maxim Group noted, “We believe the management-estimated ponatinib launch timeline is a bit optimistic. If FDA approval comes a quarter...

Maxim Group reiterated a Buy rating on American Superconductor Corp. (NASDAQ: AMSC) and a price target of $7. Maxim Group noted, “Following better-than-expected FY1Q12 growth, AMSC guided to revenue declines in FY2Q12. While this trims our FY12 EPS estimate by ($0.16) to ($0.84), we believe (1)...

Maxim Group reiterated a Buy rating on Cree (NASDAQ: CREE) and a price target of $38. Maxim Group noted, “With no major price cuts announced and reports of growth of mid-to-high single digits for our U.S. LED distributor contacts and 20%+ for its major manufacturing peers, we expect CREE's FY4Q12...

In a report published Monday, Maxim Group reiterated its Buy rating and $7.00 price target on American Superconductor Corporation (NASDAQ: AMSC). Maxim Group noted, “In AMSC's FY1Q12 report on August 2, revenue remains the critical factor, in our view, given its dire need to surpass fixed costs....

In a report published Monday, Maxim Group reiterated its Sell rating and $9.00 price target on First Solar (NASDAQ: FSLR). Maxim Group noted, “Boosted by the start of Topaz, AV Solar, and the recognition of Silver State North, we expect higher-margin project revenue to rise to ~90% of the total in...

In a report published Friday, Maxim Group reiterated its Sell rating and $23.00 price target on Veeco Instruments (NASDAQ: VECO). Maxim Group noted, “Once again distinguishing itself from AIXG, VECO delivered better-than-expected results characterized by still-high margins and positive FCF, even...

In a report published Friday, Maxim Group reiterated its Buy rating on Qihoo 360 Technology Company (NYSE: QIHU), but lowered its price target from $24.00 to $21.00. Maxim Group noted, “Our channel checks show that QIHU's self-developed search engine is the default tool of online video search in...

Maxim Group maintained a Buy rating on Tesla Motors (NASDAQ: TSLA) and a $50 price target. Maxim Group wrote, “While TSLA reported 2Q12 downside, we expect attention to focus solely on trends for the Model S that do not take the stage until 2H12. While production has kicked off slower than planned...

In a report published Wednesday, Maxim Group upgraded its rating on Zhongpin (NASDAQ: HOGS) from Hold to Buy, and established a price target of $13.50. Maxim Group noted, “Our recent channel checks show that, despite the tough economic environment and adjusting bank lending policies, the Chinese...